PegBio 派格生物 Pre-IPO: R&D Deceleration
PegBio plans to raise up to $100m for a Hong Kong listing. We examined its latest prospectus and noted besides massive delays spotted in last PHIP...
396 Views
HK Short Interest Weekly: China Mobile, Sinopec, Smic, CNOOC, Meituan, Kuaishou
We analyzed the latest HK SFC report for aggregate short position as of Apr 11th and highlight short interest changes in China Mobile, Sinopec,...
563 Views
ECM Weekly (14 Apr 2025) - Suzuki, EBOS, Hengrui Pharma, Zenergy, Chagee, LG India, Huge Dental
Aequitas Research's weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.
961 Views
Hengrui (恒瑞医药) A/H Listing: An Updated Comparison with Hansoh
Jiangsu Hengrui Medicine aims to raise around US$2bn in its H-share listing. In this note we provided an updated comparison with its close peer...
544 Views
Innovent Biologics Inc (1801 HK): 2024 Product Sales Jump 44% and Loss Narrows; Momentum to Continue
Innovent Biologics reports impressive 2024 results with revenue up 52% and net loss narrowing by 91%. The company has set an ambitious growth...
482 Views